Abivax Completes its $920 Million Public Offering

Biotechnology company Abivax SA announced the completion of its $920 million public offering, issuing 7,360,000 American Depositary Shares (ADS) in the United States. This transaction includes the full exercise of the over-allotment option. After deducting expenses, the net proceeds are approximately $874.1 million. These funds will finance the company's operations through the fourth quarter of 2029.

Abivax's ADSs are listed on the Nasdaq Global Market under the symbol "ABVX", while its ordinary shares are listed on Euronext Paris with the same symbol. Investment banks, including Leerink Partners and Morgan Stanley, were involved in the offering.